Metformin: A Potential Therapeutic Tool for Rheumatologists

Area of Science:

• Immunology
• Pharmacology
• Endocrinology

Background:

• Metformin is a primary oral antihyperglycemic agent for type 2 diabetes.
• It indirectly activates 5' Adenosine Monophosphate-activated Protein Kinase (AMPK).
• AMPK activation is linked to anti-inflammatory mechanisms and immune cell modulation.

Purpose of the Study:

• To explore the anti-inflammatory potential of metformin.
• To evaluate the rationale for repurposing metformin in autoimmune and inflammatory conditions.
• To review existing evidence on metformin's effects in rheumatologic diseases.

Main Methods:

• Review of experimental and clinical studies on metformin's anti-inflammatory and immunomodulatory effects.
• Analysis of AMPK-mediated pathways, including NF-κB and JAK/STAT signaling.
• Examination of metformin's impact on T lymphocytes and innate immune cells.

Main Results:

• Metformin, via AMPK, inhibits pro-inflammatory pathways like NF-κB and JAK/STAT.
• AMPK activation by metformin influences T lymphocytes and innate immune cells.
• Studies show metformin's benefits in animal and human rheumatologic diseases, particularly rheumatoid arthritis.

Conclusions:

• Metformin's AMPK-mediated anti-inflammatory actions provide a strong basis for its repurposing in inflammatory and autoimmune diseases.
• While experimental data are promising, a lack of robust clinical trials limits its current use by rheumatologists.
• Metformin offers benefits to rheumatologic patients with co-occurring conditions like obesity, type 2 diabetes, or steroid-induced diabetes.